Results 71 to 80 of about 11,328,563 (174)

Perivascular Spaces as Determinants of Amyloid, Tau, and Vascular Biomarker Progression

Annals of Neurology, Volume 100, Issue 4, Page 695-708, October 2026.
Objective Magnetic resonance imaging (MRI)‐visible enlarged perivascular spaces (PVS) are markers of cerebral small vessel disease (SVD) and aging, processes implicated in both neurodegenerative and cerebrovascular pathologies. However, longitudinal positron emission tomography (PET) studies examining PVS as a mechanism underlying Alzheimer's disease ...
Audrey Low, Jeffrey L. Gunter, Mingzhao Hu, Sheelakumari Raghavan, Scott A. Przybelski, Christopher G. Schwarz, Kejal Kantarci, Val J. Lowe, Ronald C. Petersen, Jonathan Graff‐Radford, Clifford R. Jack Jr, Prashanthi Vemuri   +11 more
wiley   +1 more source

Utilizing Advanced Artificial Intelligence for Automated Detection and Segmentation of Amyloid‐Related Imaging Abnormality (ARIA)

Alzheimer's & Dementia
AbstractBackgroundThe recent breakthrough in monoclonal antibody treatment for Alzheimer’s disease (AD) has ushered in a new phase in AD healthcare. However, associated amyloid‐related imaging abnormalities (ARIA) present a significant risk to patients, necessitating careful monitoring.
Xie, Long, Yushkevich, Paul A., Das, Sandhitsu R., Wolk, David A, Gibson, Eli   +4 more
openaire   +1 more source

Case report and risk factor analysis of amyloid-related imaging abnormalities induced by lecanemab in Alzheimer's disease [PDF]

Zhenduanxue lilun yu shijian
Amyloid-related imaging abnormalities (ARIA) represent a significant safety concern that requires attention during the treatment of Alzheimer's disease (AD) with lecanemab, and their occurrence is associated with multiple factors.
XU Chenhaoyi, LIU Jingwen, FANG Min
doaj   +1 more source

Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report

Journal of Alzheimer's Disease Reports
Lecanemab is an anti-amyloid-β protofibril antibody that slows cognitive decline in early Alzheimer's disease. Although amyloid-related imaging abnormalities (ARIA) occur predominantly early in treatment, reports of hemorrhagic events during extended ...
Yugo Takahashi, Naoyuki Shiraishi, Akihiro Tsukahara, Yukari Matsuda, Takuya Nishina, Hiroo Yoshikawa, Takashi Uzu, Etsuro Mori   +7 more
doaj   +1 more source

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy

Frontiers in Radiology
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Houman Sotoudeh, Mohammadreza Alizadeh, Ramin Shahidi, Parnian Shobeiri, Zahra Saadatpour, C. Austin Wheeler, Marissa Natelson Love, Manoj Tanwar   +7 more
doaj   +1 more source

Abstract Number ‐ 224: Stroke Mimic—Patient with Symptomatic Amyloid‐Related Imaging Abnormalities Presenting with Stroke‐like Symptoms.

, 2023
Introduction Amyloid‐related imaging abnormalities (ARIA) are rare phenomena in patients taking monoclonal antibodies directed against amyloid beta in Alzheimer’s disease clinical trials.
Clos, Siara, Siara Clos, Blanden, Adam R, Michael Kmeid, Kmeid, Michael, Hesham Masoud, Adam R Blanden, Masoud, Hesham, Kaur, Navreet, Navreet Kaur   +9 more
core   +1 more source

Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms

Three monoclonal antibodies directed against specific forms of the amyloid-β (Aβ) peptide have been granted accelerated or traditional approval by the FDA as treatments for Alzheimer disease, representing the first step towards bringing disease-modifying
Greenberg S. M., van Veluw S. J., Bax F., Bax, F.   +3 more
core   +1 more source

APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD study. [PDF]

Alzheimers Dement
INTRODUCTION We evaluated whether apolipoprotein E ( APOE εε4) genotype‐guided lecanemab escalation mitigates the APOE εε4 ...
Kang H, Jang H, Ahn J, Na DL, Lee JH, Kim EJ, Chun MY, Cho SH, Kim BC, Kim SE, Sohn G, Yun J, Lee JS, Park KC, Park HK, Kim YJ, Lee K, Yim S, Kim S, Kim JP, Kim HJ, Lim JS, Seo SW.   +22 more
europepmc   +2 more sources

Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease

CPT: Pharmacometrics & Systems Pharmacology
To inform an efficient development of new investigational anti‐amyloid beta (anti‐Aβ) monoclonal antibodies (mAbs), a modeling‐and‐simulation‐based strategy was proposed.
Sagar S. Bachhav, Ana Victoria Ponce‐Bobadilla, Diana Clausznitzer, Sven Stodtmann, Hao Xiong   +4 more
doaj   +1 more source

Cerebral Amyloid Angiopathy: Clinical Presentation, Sequelae and Neuroimaging Features—An Update

Biomedicines
The prevalence of cerebral amyloid angiopathy (CAA) has been shown to increase with age, with rates reported to be around 50–60% in individuals over 80 years old who have cognitive impairment. The disease often presents as spontaneous lobar intracerebral
Stefan Weidauer, Elke Hattingen
doaj   +1 more source